Saratoga Research & Investment Management trimmed its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 2.1% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 253,156 shares of the company’s stock after selling 5,486 shares during the period. Johnson & Johnson makes up about 2.5% of Saratoga Research & Investment Management’s investment portfolio, making the stock its 18th largest holding. Saratoga Research & Investment Management’s holdings in Johnson & Johnson were worth $35,371,000 at the end of the most recent quarter.
A number of other institutional investors and hedge funds have also modified their holdings of JNJ. Harding Loevner LP bought a new position in Johnson & Johnson in the 2nd quarter worth $106,000. IHT Wealth Management LLC raised its holdings in Johnson & Johnson by 46.4% in the 2nd quarter. IHT Wealth Management LLC now owns 10,942 shares of the company’s stock worth $122,000 after purchasing an additional 3,467 shares during the period. Mountain Capital Investment Advisors Inc bought a new position in Johnson & Johnson in the 2nd quarter worth $124,000. Lenox Wealth Management Inc. raised its holdings in Johnson & Johnson by 1.7% in the 2nd quarter. Lenox Wealth Management Inc. now owns 1,457 shares of the company’s stock worth $193,000 after purchasing an additional 24 shares during the period. Finally, Intercontinental Wealth Advisors LLC bought a new position in Johnson & Johnson in the 2nd quarter worth $200,000. Institutional investors and hedge funds own 67.23% of the company’s stock.
A number of equities analysts recently commented on JNJ shares. Zacks Investment Research cut Johnson & Johnson from a “buy” rating to a “hold” rating in a report on Tuesday, December 12th. BMO Capital Markets raised their target price on Johnson & Johnson to $161.00 and gave the stock an “outperform” rating in a report on Tuesday, December 12th. Vetr raised Johnson & Johnson from a “hold” rating to a “buy” rating and set a $147.14 target price on the stock in a report on Wednesday, December 20th. JPMorgan Chase cut Johnson & Johnson from an “overweight” rating to a “neutral” rating in a report on Tuesday, January 2nd. Finally, Royal Bank of Canada reaffirmed a “buy” rating on shares of Johnson & Johnson in a report on Tuesday, January 9th. Five research analysts have rated the stock with a sell rating, eight have issued a hold rating and nine have issued a buy rating to the company. Johnson & Johnson presently has an average rating of “Hold” and a consensus target price of $144.58.
Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings data on Tuesday, January 23rd. The company reported $1.74 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.72 by $0.02. The firm had revenue of $20.20 billion during the quarter, compared to analyst estimates of $20.08 billion. Johnson & Johnson had a return on equity of 29.00% and a net margin of 1.70%. The business’s quarterly revenue was up 11.5% compared to the same quarter last year. During the same quarter last year, the business posted $1.58 earnings per share. analysts predict that Johnson & Johnson will post 8.11 earnings per share for the current fiscal year.
In other news, VP Paulus Stoffels sold 155,342 shares of the firm’s stock in a transaction dated Thursday, February 15th. The stock was sold at an average price of $129.86, for a total transaction of $20,172,712.12. Following the completion of the transaction, the vice president now owns 357,906 shares in the company, valued at $46,477,673.16. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Company insiders own 0.22% of the company’s stock.
About Johnson & Johnson
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. Its Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, RoC, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.